Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

Rising prevalence of diabetes, recent product approvals & product launches in the market are the major factors driving the market for incretin-based drugs.

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Novo Nordisk's amycretin trial results highlight significant weight loss in adults with obesity, with further clinical ...

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on ...

Incretin-mimetic drugs contribute to dramatic weight loss, but this does not solely mean fat loss. In this article, we ...

With your help, your community can take action too. Urge your mayor to take action on climate change by joining the Earth Hour City Challenge! To avoid the worst effects of climate change, we need to ...

Lake-effect snow brings heavy snowfall to some parts of North America Lake-effect snow is most common around the Great Lakes region in the US and Canada during late autumn and winter. It can lead ...

For Q4 2024, Lilly now expects global revenue of approximately $13.5bn, a 45% increase from Q4 2023. This growth is driven by the strong performance of its incretin-based drugs, including diabetes ...

3 being typically much lower in humans than those that cause the effects shown in the rats. 1 Furthermore, studies in other animals and humans did not show these effects, meaning claims that the ...